Stanole--nowa perspektywa w leczeniu hipercholesterolemii?

Translated title of the contribution: Stanols--a new perspective in treatment of hypercholesterolemia?

P. Jankowski, G. Bilo, L. Bryniarski, E. Bryniarska-Mirek, A. Pajak

Research output: Contribution to journalArticle

Abstract

Since the unfavorable impact of hypercholesterolemia on the cardiovascular system has been proven, effective, inexpensive and easy to use cholesterol-lowering treatment options have been looked for. In the 1990s as the effect of a few decades of research, stanols have been introduced as new cholesterol-lowering agents. Stanols are derivates of plant sterols, which act through inhibition of intestinal cholesterol absorption. Their incorporation into normal diet fats has led to a significant reduction of both total and LDL cholesterol in investigated subjects, also in those on cholesterol-lowering diet or taking cholesterol-lowering drugs. When the dose considered optimal, i.e. 2-3 g/d, was used, the average reduction was 10% for total and 14% for LDL cholesterol. So far no adverse effects of stanols and no influence on the taste of food have been observed. The possible role of stanols in primary and secondary prevention of cardiovascular diseases still remains to be verified. It seems, however, that stanols have a potential to become a significant element in the treatment of hypercholesterolemia and in preventing its consequences.

Original languagePolish
Pages (from-to)655-658
Number of pages4
JournalPrzeglad Lekarski
Volume57
Issue number11
Publication statusPublished - 2000

Fingerprint

Hypercholesterolemia
Cholesterol
LDL Cholesterol
Diet
Therapeutics
Phytosterols
Intestinal Absorption
Primary Prevention
Cardiovascular System
Secondary Prevention
Cardiovascular Diseases
Fats
Food
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jankowski, P., Bilo, G., Bryniarski, L., Bryniarska-Mirek, E., & Pajak, A. (2000). Stanole--nowa perspektywa w leczeniu hipercholesterolemii? Przeglad Lekarski, 57(11), 655-658.

Stanole--nowa perspektywa w leczeniu hipercholesterolemii? / Jankowski, P.; Bilo, G.; Bryniarski, L.; Bryniarska-Mirek, E.; Pajak, A.

In: Przeglad Lekarski, Vol. 57, No. 11, 2000, p. 655-658.

Research output: Contribution to journalArticle

Jankowski, P, Bilo, G, Bryniarski, L, Bryniarska-Mirek, E & Pajak, A 2000, 'Stanole--nowa perspektywa w leczeniu hipercholesterolemii?', Przeglad Lekarski, vol. 57, no. 11, pp. 655-658.
Jankowski P, Bilo G, Bryniarski L, Bryniarska-Mirek E, Pajak A. Stanole--nowa perspektywa w leczeniu hipercholesterolemii? Przeglad Lekarski. 2000;57(11):655-658.
Jankowski, P. ; Bilo, G. ; Bryniarski, L. ; Bryniarska-Mirek, E. ; Pajak, A. / Stanole--nowa perspektywa w leczeniu hipercholesterolemii?. In: Przeglad Lekarski. 2000 ; Vol. 57, No. 11. pp. 655-658.
@article{c3b7ef4cd8a640f9b7cb744e6ef0eee3,
title = "Stanole--nowa perspektywa w leczeniu hipercholesterolemii?",
abstract = "Since the unfavorable impact of hypercholesterolemia on the cardiovascular system has been proven, effective, inexpensive and easy to use cholesterol-lowering treatment options have been looked for. In the 1990s as the effect of a few decades of research, stanols have been introduced as new cholesterol-lowering agents. Stanols are derivates of plant sterols, which act through inhibition of intestinal cholesterol absorption. Their incorporation into normal diet fats has led to a significant reduction of both total and LDL cholesterol in investigated subjects, also in those on cholesterol-lowering diet or taking cholesterol-lowering drugs. When the dose considered optimal, i.e. 2-3 g/d, was used, the average reduction was 10{\%} for total and 14{\%} for LDL cholesterol. So far no adverse effects of stanols and no influence on the taste of food have been observed. The possible role of stanols in primary and secondary prevention of cardiovascular diseases still remains to be verified. It seems, however, that stanols have a potential to become a significant element in the treatment of hypercholesterolemia and in preventing its consequences.",
author = "P. Jankowski and G. Bilo and L. Bryniarski and E. Bryniarska-Mirek and A. Pajak",
year = "2000",
language = "Polish",
volume = "57",
pages = "655--658",
journal = "Przeglad Lekarski",
issn = "0033-2240",
publisher = "Fundacja Lekarzy Polskich-Pro-Medica",
number = "11",

}

TY - JOUR

T1 - Stanole--nowa perspektywa w leczeniu hipercholesterolemii?

AU - Jankowski, P.

AU - Bilo, G.

AU - Bryniarski, L.

AU - Bryniarska-Mirek, E.

AU - Pajak, A.

PY - 2000

Y1 - 2000

N2 - Since the unfavorable impact of hypercholesterolemia on the cardiovascular system has been proven, effective, inexpensive and easy to use cholesterol-lowering treatment options have been looked for. In the 1990s as the effect of a few decades of research, stanols have been introduced as new cholesterol-lowering agents. Stanols are derivates of plant sterols, which act through inhibition of intestinal cholesterol absorption. Their incorporation into normal diet fats has led to a significant reduction of both total and LDL cholesterol in investigated subjects, also in those on cholesterol-lowering diet or taking cholesterol-lowering drugs. When the dose considered optimal, i.e. 2-3 g/d, was used, the average reduction was 10% for total and 14% for LDL cholesterol. So far no adverse effects of stanols and no influence on the taste of food have been observed. The possible role of stanols in primary and secondary prevention of cardiovascular diseases still remains to be verified. It seems, however, that stanols have a potential to become a significant element in the treatment of hypercholesterolemia and in preventing its consequences.

AB - Since the unfavorable impact of hypercholesterolemia on the cardiovascular system has been proven, effective, inexpensive and easy to use cholesterol-lowering treatment options have been looked for. In the 1990s as the effect of a few decades of research, stanols have been introduced as new cholesterol-lowering agents. Stanols are derivates of plant sterols, which act through inhibition of intestinal cholesterol absorption. Their incorporation into normal diet fats has led to a significant reduction of both total and LDL cholesterol in investigated subjects, also in those on cholesterol-lowering diet or taking cholesterol-lowering drugs. When the dose considered optimal, i.e. 2-3 g/d, was used, the average reduction was 10% for total and 14% for LDL cholesterol. So far no adverse effects of stanols and no influence on the taste of food have been observed. The possible role of stanols in primary and secondary prevention of cardiovascular diseases still remains to be verified. It seems, however, that stanols have a potential to become a significant element in the treatment of hypercholesterolemia and in preventing its consequences.

UR - http://www.scopus.com/inward/record.url?scp=0034574239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034574239&partnerID=8YFLogxK

M3 - Articolo

C2 - 11293214

AN - SCOPUS:0034574239

VL - 57

SP - 655

EP - 658

JO - Przeglad Lekarski

JF - Przeglad Lekarski

SN - 0033-2240

IS - 11

ER -